2025
Brain-derived neurotrophic factor and cytokines as predictors of cognitive impairment in adolescent and young adult cancer patients receiving chemotherapy: a longitudinal study
Trudeau J, Ng D, Sayer M, Tan C, Ke Y, Chan R, Chan A. Brain-derived neurotrophic factor and cytokines as predictors of cognitive impairment in adolescent and young adult cancer patients receiving chemotherapy: a longitudinal study. BMC Cancer 2025, 25: 1045. PMID: 40597835, PMCID: PMC12211463, DOI: 10.1186/s12885-025-14430-3.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorNon-cancer controlsCancer-related cognitive impairmentYoung adult cancer patientsAdult cancer patientsCambridge Neuropsychological Test Automated BatteryPost-chemotherapyIL-10TNF-aCancer patientsNeurotrophic factorModulation of brain-derived neurotrophic factorPlasma levels of cytokinesPlasma brain-derived neurotrophic factorBrain-derived neurotrophic factor expressionHigher brain-derived neurotrophic factorAssociated with BDNF levelsLevels of cytokinesAge-matched NCCognitive impairmentTrial registrationThe studyChemotherapy statusDysregulated cytokine signalingPlasma cytokinesIFN-gAssociation between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis
Theprungsirikul P, Wang R, Ahmad I, Neparidze N, Ma X, Chang S, Wang S. Association between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis. Clinical Lymphoma Myeloma & Leukemia 2025 DOI: 10.1016/j.clml.2025.06.016.Peer-Reviewed Original ResearchSmoldering Multiple MyelomaSmoldering multiple myeloma patientsMultiple myelomaPatient demographicsProgression to multiple myelomaSymptomatic multiple myelomaDevelopment of hypercalcemiaCox proportional hazards modelsRisk stratification modelConfidence intervalsNon-cancer controlsEstimate hazard ratiosProportional hazards modelNon-cancer patientsSymptomatic MMRandom sample of Medicare beneficiariesSMM patientsRenal failureAnalyzed SurveillanceSEER-MedicareNatural history modelHazard ratioBone diseasePatientsSample of Medicare beneficiaries
2024
Dynamin-1 is a potential mediator in cancer-related cognitive impairment
Ng D, Hudson C, Nguyen T, Gupta S, Koh Y, Acharya M, Chan A. Dynamin-1 is a potential mediator in cancer-related cognitive impairment. Neurotherapeutics 2024, 22: e00480. PMID: 39516074, PMCID: PMC11742811, DOI: 10.1016/j.neurot.2024.e00480.Peer-Reviewed Original ResearchConceptsCancer-related cognitive impairmentFemale mouse modelNon-cancer controlsSpatial recognition memoryConsequences of cancer treatmentYoung adult cancerCytotoxic treatmentControl miceHippocampal CA1Cancer patientsMouse modelSynaptic activityAdult cancersCA3 subregionNeurological consequencesAnimal modelsCognitive impairmentAnimal studiesHuman studiesCancer treatmentNon-cancer participantsTherapeutic targetCancerExposure to cancerChemotherapyFunctional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study
Sedrak M, Sun C, Bae M, Freedman R, Magnuson A, O’Connor T, Moy B, Wildes T, Klepin H, Chapman A, Tew W, Dotan E, Fenton M, Kim H, Katheria V, Muss H, Cohen H, Gross C, Ji J. Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study. Journal Of Cancer Survivorship 2024, 18: 1131-1143. PMID: 38678525, PMCID: PMC11324395, DOI: 10.1007/s11764-024-01594-3.Peer-Reviewed Original ResearchEarly-stage breast cancerPF-10 scorePF-10Physical functionNon-cancer controlsFunctional declineBC controlOlder breast cancer survivorsRAND 36-Item Short FormBreast cancerCohort of older adultsOlder womenBreast cancer survivorsImprove health outcomesPhysical function subscalePhysical function declineAccelerated functional declineBreast Cancer StudyCancer survivorsFunction subscaleHealth outcomesGroup of womenOlder adultsControl groupShort form
2023
Brain-derived neurotrophic factor as a biomarker in cancer-related cognitive impairment among adolescent and young adult cancer patients
Ng D, Cheng I, Wang C, Tan C, Toh Y, Koh Y, Ke Y, Foo K, Chan R, Ho H, Chew L, bin Harunal Rashid M, Chan A. Brain-derived neurotrophic factor as a biomarker in cancer-related cognitive impairment among adolescent and young adult cancer patients. Scientific Reports 2023, 13: 16298. PMID: 37770565, PMCID: PMC10539508, DOI: 10.1038/s41598-023-43581-1.Peer-Reviewed Original ResearchConceptsCancer-related cognitive impairmentYoung adult cancer patientsBrain-derived neurotrophic factorAdult cancer patientsCambridge Neuropsychological Test Automated BatteryCancer participantsNon-cancer controlsPlasma brain-derived neurotrophic factorSociodemographic variablesBDNF levelsCognitive impairmentBrain-derived neurotrophic factor Val66MetCancer patientsAssociated with worse attentionNeurotrophic factorBrain-derived neurotrophic factor levelsAssociated with enhanced executive functionBaseline BDNF levelsFACT-CogPlasma BDNF levelsPsychological distressImprove cognitive functionBaseline cognitionPost-baselineEnzyme-linked immunosorbent assay
2022
Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma
Miller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. Journal Of Geriatric Oncology 2022, 13: 635-643. PMID: 34996724, PMCID: PMC9232862, DOI: 10.1016/j.jgo.2021.12.012.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaNon-cancer controlsRenal cell carcinomaMRCC diagnosisMild cognitive impairmentCell carcinomaRisk factorsCognitive impairmentOlder adultsProportional hazards modelNew cancer treatmentsCohort entryOlder patientsSurgical therapyMAIN OUTCOMEExclusion criteriaAgent useDisease processHazards modelPatientsMedicare datasetCancer treatmentDiagnosisDementiaCarcinoma
2021
Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations
Miller S, Wilson L, Greiner M, Pritchard J, Zhang T, Kaye D, Cohen H, Dinan M. Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations. Innovation In Aging 2021, 5: 703-703. PMCID: PMC8969788, DOI: 10.1093/geroni/igab046.2613.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaProportional hazards regressionOral anticancer agentsMRCC diagnosisCell carcinomaHazards regressionRisk factorsCox proportional hazards regressionOlder adultsNon-cancer controlsMild cognitive impairmentCohort entryRenal dysfunctionOnly patientsSurgical therapyWhite patientsBlack patientsSEER-MedicareDementia onsetMAIN OUTCOMEExclusion criteriaHigh riskPatientsCognitive impairmentCancer treatment is associated with a measurable decrease in live births in a large, population-based study
Garg D, Meeks H, Johnstone E, Berga S, Smith K, Hotaling J, Letourneau J. Cancer treatment is associated with a measurable decrease in live births in a large, population-based study. F&S Reports 2021, 2: 462-467. PMID: 34934988, PMCID: PMC8655402, DOI: 10.1016/j.xfre.2021.08.004.Peer-Reviewed Original ResearchIncidence rate ratiosPopulation-based studyLive birth rateAge-matched controlsLive birthsCancer survivorsCancer typesHealthy controlsBreast cancerLower live birth ratesCancer treatmentCentral nervous system cancerRetrospective cohort studyFemale cancer patientsNon-cancer controlsNervous system cancersAge 18 yearsCommon cancer typesSoft tissue cancerBirth rateCohort studyGastrointestinal cancerCancer patientsSystem cancersMAIN OUTCOMELung microbiome alterations in NSCLC patients
Zheng L, Sun R, Zhu Y, Li Z, She X, Jian X, Yu F, Deng X, Sai B, Wang L, Zhou W, Wu M, Li G, Tang J, Jia W, Xiang J. Lung microbiome alterations in NSCLC patients. Scientific Reports 2021, 11: 11736. PMID: 34083661, PMCID: PMC8175694, DOI: 10.1038/s41598-021-91195-2.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNon-small cell lung cancer patientsRare speciesOral taxaLung microbiotaDiverse array of microbesNon-cancer controlsLobectomy samplesArray of microbesGlobal microbial compositionAssociated with lung cancer progressionLung cancerLung microbiome compositionBronchoscopy samplesPseudomonas entomophilaMetagenomic sequencingBronchoalveolar lavageLactobacillus rossiaeBacteroides pyogenesMicrobiota dysbiosisMicrobial communitiesMicrobiome compositionPaenibacillus odoriferMicrobial compositionLung microbiota dysbiosis
2018
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian carcinomaSerous ovarian carcinomaIL-6Ovarian cancerOvarian carcinomaE-cadHigh-grade serous ovarian adenocarcinomaEarly-stage ovarian cancerROC analysisEarly detectionMajority of patientsLethal gynecologic malignancyStage ovarian cancerOvarian cancer patientsBenign gynecologic pathologyNon-cancer controlsSerous ovarian adenocarcinomaEffective cancer screeningSerous ovarian cancerMultiple biomarker panelsFour-marker panelHigh differential gene expressionGynecologic malignanciesCA 125IL-1ra
2012
Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer
YUN S, JEONG P, KIM W, KIM T, LEE Y, SONG P, CHOI Y, KIM I, MOON S, KIM W. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal Of Oncology 2012, 41: 1871-1878. PMID: 22961325, DOI: 10.3892/ijo.2012.1622.Peer-Reviewed Original ResearchConceptsBladder cancerCell-free miRNAsMiR-200aMiR-145Transitional cell carcinomaBladder cancer patientsNon-cancer controlsHealthy normal controlsMiR-145 levelsMiR-200a levelsCell-free microRNAsNMIBC recurrenceIndependent predictorsClinicopathological featuresCell carcinomaCancer patientsPrognostic biomarkerUrinary bladderHigh riskNoninvasive biomarkersNormal controlsAccurate biomarkersMultivariate analysisPatientsCancerThe impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes
Wang R, Gross CP, Frick K, Xu X, Long J, Raza A, Galili N, Zikria J, Guan Y, Ma X. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leukemia Research 2012, 36: 1370-1375. PMID: 22917770, PMCID: PMC3458648, DOI: 10.1016/j.leukres.2012.07.020.Peer-Reviewed Original ResearchConceptsCost of careMyelodysplastic syndromeMDS patientsMedicare expendituresComparative cost-effectiveness studyCohort of patientsTwo-year survivalNon-cancer controlsCost-effectiveness studiesElderly patientsPrevalent cancerEconomic burdenPatientsMajor subtypesSurvivalCareSyndromeUnited StatesHMAsSurvival probabilityEarly periodCohortAgentsCancerSubtypes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply